HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer JClin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proce National Acad Sci USA. 2003;100:8418–8423.
   PubMed Web of Science ®Google Scholar
• Ashar HR, Cherath L, Przybysz KM, Chada K. Genomic characterization of human HMGIC, amember of the accessory transcription factor family found at translocation breakpoints in lipomas. Genomics. 1996;31:207–214. doi:10.1006/geno.1996.0033.
   PubMed Web of Science ®Google Scholar
• Cleynen I. Van de Ven WJ. The HMGA proteins: Amyriad of functions (Review). IntJOncol. 2008;32:289–305.
   Google Scholar
• Pfannkuche K, Summer H, Li O, Hescheler J, Droge P. The high mobility group protein HMGA2: a co-regulator of chromatin structure and pluripotency in stem cells? Stem Cell Rev Reports. 2009;5:224–230. doi:10.1007/s12015-009-9078-9.
   PubMed Web of Science ®Google Scholar
• Zhao XP, Zhang H, Jiao JY, Tang DX, Wu YL, Pan CB. Overexpression of HMGA2 promotes tongue cancer metastasis through EMT pathway. JTransl Med. 2016;14:26. doi:10.1186/s12967-016-0777-0.
   PubMed Web of Science ®Google Scholar
• Gao X, Dai M, Li Q, Wang Z, Lu Y, Song Z. HMGA2 regulates lung cancer proliferation and metastasis. Thoracic Cancer. 2017;8:501–510. doi:10.1111/1759-7714.12476.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. JClin Invest. 2009;119:1420–1428. doi:10.1172/JCI39104.
   PubMed Web of Science ®Google Scholar
• Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, D’Armiento J, Chada K. HMGA2 is adriver of tumor metastasis. Cancer Res. 2013;73:4289–4299. doi:10.1158/0008-5472.CAN-12-3848.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu X, Li AY, Chen L, Lai L, Lin HH, Hu S, Yao L, PengJ, Loera S, etal. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clini Cancer Res. 2011;17:2570–2580. doi:10.1158/1078-0432.CCR-10-2542.
   PubMed Web of Science ®Google Scholar
• Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J, Wei -J-J, etal. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 2011;71(2):349–359. doi:10.1158/0008-5472.CAN-10-2550.
   PubMed Web of Science ®Google Scholar
• Motoyama K, Inoue H, NakamuraY, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clini Cancer Res. 2008;14:2334–2340. doi:10.1158/1078-0432.CCR-07-4667.
   PubMed Web of Science ®Google Scholar
• Pallante P, Sepe R, Puca F, Fusco A. High mobility group aproteins as tumor markers. Frontiers Med. 2015;2:15. doi:10.3389/fmed.2015.00015.
   PubMed Web of Science ®Google Scholar
• Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene. 1994;9:2145–2152.
   PubMed Web of Science ®Google Scholar
• Mohler PJ, Kreda SM, Boucher RC, Sudol M, Stutts MJ, Milgram SL. Yes-associated protein 65 localizes p62 c-Yes to the apical compartment of airway epithelia by association with EBP50. JCell Biol. 1999;147:879–890. doi:10.1083/jcb.147.4.879.
   PubMed Web of Science ®Google Scholar
• Espanel X, Sudol M. Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. JBiol Chem. 2001;276:14514–14523. doi:10.1074/jbc.M008568200.
   PubMedGoogle Scholar
• Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811–828. doi:10.1016/j.cell.2015.10.044.
   PubMed Web of Science ®Google Scholar
• Shao DD, Xue W, Krall EB, Bhutkar A, PiccioniF, WangX, SchinzelA, SoodS, RosenbluhJ, KimJ, etal. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158:171–184. doi:10.1016/j.cell.2014.06.004.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM, Fu K, Datta K, Palermo N, Chen Y, etal. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol. 2015;35(8):1350–1362. doi:10.1128/MCB.00102-15.
   PubMed Web of Science ®Google Scholar
• Chen X, Li C, He T, Mao J, Li C, Lyu J, Meng QH. Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression. Cancer Biol Ther. 2016;17:507–514. doi:10.1080/15384047.2016.1156273.
   PubMed Web of Science ®Google Scholar
• Yang Y, Meng H, Peng Q, Yang X, Gan R, Zhao L, Chen Z, Lu J, Meng QH. Downregulation of microRNA-21 expression restrains non-small cell lung cancer cell proliferation and migration through upregulation of programmed cell death 4. Cancer Gene Ther. 2015;22(1):23–29. doi:10.1038/cgt.2014.66.
   PubMed Web of Science ®Google Scholar
• Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, SiorisT, Salo J, Karjalainen A, Knuutila S, Anttila S. Increased expression of high mobility group Aproteins in lung cancer. JPathol. 2006;209(2):206–212. doi:10.1002/path.1960.
   Google Scholar
• Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Peña JG, TreviñoV. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PloS One. 2013;8:e74250. doi:10.1371/journal.pone.0074250.
   PubMed Web of Science ®Google Scholar
• MeyerB, LoeschkeS, SchultzeA, WeigelT, SandkampM, GoldmannT, VollmerE, BullerdiekJ. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 2007;46(7):503–511. doi:10.1002/mc.20235.
   PubMed Web of Science ®Google Scholar
• Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L, et al. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer. 2008;44:1015–1021. doi:10.1016/j.ejca.2008.02.039.
   PubMed Web of Science ®Google Scholar
• Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Modern Pathol. 2008;22:43–49. doi:10.1038/modpathol.2008.140.
   PubMed Web of Science ®Google Scholar
• Fabjani G, Tong D, Wolf A, Roka S, Leodolter S, Hoecker P, Fischer MB, Jakesz R, Zeillinger R, et al. HMGA2 is associated with invasiveness but not asuitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep. 2005;14:737–741.
   PubMed Web of Science ®Google Scholar
• Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315:1576–1579. doi:10.1126/science.1137999.
   PubMed Web of Science ®Google Scholar
• Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, SchuldenfreiA, Kowalski J, Bhattacharya R, Ashfaq R, Resar LMS, etal. HMGA2 participates in transformation in human lung cancer. Molecular Cancer Res. 2008;6:743–750. doi:10.1158/1541-7786.MCR-07-0095.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Ueda Y, Akaboshi S, HinoY, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am JPathol. 2009;174:854–868. doi:10.2353/ajpath.2009.080523.
   PubMed Web of Science ®Google Scholar
• Shi Z, Li X, Wu D, Tang R, Chen R, Xue S, Sun X. Silencing of HMGA2 suppresses cellular proliferation, migration, invasion, and epithelial–mesenchymal transition in bladder cancer. Tumour Biol. 2016;37:7515–7523. doi:10.1007/s13277-015-4625-2.
   PubMedGoogle Scholar
• Shi Z, Wu D, Tang R, Li X, Chen R, XueS, ZhangC, Sun X. Silencing of HMGA2 promotes apoptosis and inhibits migration and invasion of prostate cancer cells. JBiosci. 2016;41:229–236. doi:10.1007/s12038-016-9603-3.
   Google Scholar
• Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–273. doi:10.1038/nrc2620.
   PubMed Web of Science ®Google Scholar
• Shang Y, Cai X, Fan D. Roles of epithelial-mesenchymal transition in cancer drug resistance. Curr Cancer Drug Targets. 2013;13:915–929. doi:10.2174/15680096113136660097.
   PubMed Web of Science ®Google Scholar
• Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): Abiological process in the development, stem cell differentiation, and tumorigenesis. JCell Physiol. 2017;232:3261–3272. doi:10.1002/jcp.25797.
   PubMed Web of Science ®Google Scholar
• Shell S, Park SM, Radjabi AR, Schicke lR, Kistner EO, Jewell DA, Feig C , Lengye lE , Peter ME. Let-7 expression defines two differentiation stages of cancer. Proc National Acad Sci USA. 2007;104:11400–11405.
   PubMed Web of Science ®Google Scholar
• Zhou X, Guo Y, Ye L, Long L, Wang H, Tan P, Xu M. MicroRNA-588 regulates invasion, migration and epithelial–mesenchymal transition via targeting EIF5A2 pathway in gastric cancer. Cancer Manag Res. 2018;10:5187–5197. doi:10.2147/CMAR.S176954.
   PubMed Web of Science ®Google Scholar
• Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, etal. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–2761. doi:10.1101/gad.1602907.
   PubMed Web of Science ®Google Scholar
• Reich E, Franklin RM, Shatkin AJ, Tatum EL. Action of actinomycin Don animal cells and viruses. Proc Natl Acad Sci USA. 1962;48:1238–1245. doi:10.1073/pnas.48.7.1238.
   PubMed Web of Science ®Google Scholar
• Ciechanover A. Intracellular protein degradation: from avague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Best Pract Clin Haematol. 2017;30:341–355. doi:10.1016/j.beha.2017.09.001.
   PubMed Web of Science ®Google Scholar
• Yan H, Ma YL, Gui YZ, WangSM, Wang XB, Gao F, Wang YP. MG132, aproteasome inhibitor, enhances LDL uptake in HepG2 cells invitro by regulating LDLR and PCSK9 expression. Acta Pharmacol Sin. 2014;35:994–1004. doi:10.1038/aps.2014.52.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Kadowaki M, Yoshioka H, Kambe A, Watanabe T, Kinyamu HK, Eling TE. Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells. Biochem Biophys Res Commun. 2013;430:1277–1282. doi:10.1016/j.bbrc.2012.11.137.
   PubMed Web of Science ®Google Scholar
• Jia D, Jing Y, Zhang Z, Liu L, Ding J, Zhao F, Ge C, Wang Q, Chen T, Yao M, et al. Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Res. 2014;24(2):204–217. doi: 10.1038/cr.2013.158.
   PubMed Web of Science ®Google Scholar
• Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15:642–656. doi:10.15252/embr.201438638.
   PubMed Web of Science ®Google Scholar